Distinguished in Primary Hyperoxaluria Type 1

Anne-laure L. Leclerc-Sellier

Bron, FR 
Distinguished in Primary Hyperoxaluria Type 1
Bron, FR 
OverviewLocationsClinical Research

Overview

Anne-laure Leclerc-Sellier practices in Bron, France. Leclerc-Sellier is rated as a Distinguished expert by MediFind in the treatment of Primary Hyperoxaluria Type 1. Their top areas of expertise are Nephrocalcinosis, Primary Hyperoxaluria Type 1, Primary Hyperoxaluria, Kidney Transplant, and Liver Transplant.

Their clinical research consists of co-authoring 63 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 17 articles in the study of Primary Hyperoxaluria Type 1.

Locations

Bron, France
Other Locations
Lyon, France
CHU de Montpellier
Montpellier, France
Paris, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 2 Open-label Multi-centre Study to Evaluate the Efficacy and Safety of Oxabact® to Reduce Plasma Oxalate in Subjects With Primary Hyperoxaluria Who Are on Dialysis
A Phase 2 Open-label Multi-centre Study to Evaluate the Efficacy and Safety of Oxabact® to Reduce Plasma Oxalate in Subjects With Primary Hyperoxaluria Who Are on Dialysis
Enrollment Status: Completed
Publish Date: January 10, 2022
Intervention Type: Biological
Study Phase: Phase 2
A Phase III Double-blind, Randomised Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria
A Phase III Double-blind, Randomised Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria
Enrollment Status: Completed
Publish Date: December 10, 2021
Intervention Type: Other, Biological
Study Drug: Oxabact OC5 - Oxalobacter formigenes HC-1
Study Phase: Phase 3
Early Treatment With the Monoclonal C5 Antibody Eculizumab in Pediatric Patients Affected by Shiga-toxin Related Hemolytic and Uremic Syndrome: A Phase III Prospective Randomized Controlled Therapeutic Trial Versus Placebo
Early Treatment With the Monoclonal C5 Antibody Eculizumab in Pediatric Patients Affected by Shiga-toxin Related Hemolytic and Uremic Syndrome: A Phase III Prospective Randomized Controlled Therapeutic Trial Versus Placebo
Enrollment Status: Completed
Publish Date: July 12, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 2 Less Clinical Trials

63 Total Publications

Long-term Lumasiran Therapy Final Results from a Phase 2 Open-label Extension Study in Primary Hyperoxaluria.
Long-term Lumasiran Therapy Final Results from a Phase 2 Open-label Extension Study in Primary Hyperoxaluria.
Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Published: September 22, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Leclerc-Sellier's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 19 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile